MARKET

ICPT

ICPT

Intercept
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.66
+1.33
+6.88%
After Hours: 20.66 0 0.00% 17:30 03/05 EST
OPEN
19.65
PREV CLOSE
19.33
HIGH
20.66
LOW
18.15
VOLUME
1.65M
TURNOVER
--
52 WEEK HIGH
98.03
52 WEEK LOW
18.15
MARKET CAP
682.10M
P/E (TTM)
-2.4683
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4)
Benzinga · 10h ago
The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 3)
Benzinga · 1d ago
Primary Sclerosing Cholangitis Market Share, Size, Global Growth Opportunities, Driving Factors by Manufacturers, Regions, Type and Application, Revenue Market Forecast to 2025
Mar 04, 2021 (The Expresswire) -- Global Primary Sclerosing Cholangitis Market Research report discusses the market growth drivers and challenges that the...
The Express Wire · 1d ago
Intercept Pharma (ICPT) Gets a Hold Rating from Canaccord Genuity
Canaccord Genuity analyst Edward Nash maintained a Hold rating on Intercept Pharma (ICPT) yesterday and set a price target of $43.00. The company's shares
SmarterAnalyst · 2d ago
--Analyst Actions: UBS Adjusts Intercept Pharmaceuticals' Price Target to $21 From $37 on Ocaliva Sales Estimates; Neutral Rating Kept
MT Newswires · 2d ago
Leerink Partners Keeps Their Hold Rating on Intercept Pharma (ICPT)
Leerink Partners analyst Thomas Smith reiterated a Hold rating on Intercept Pharma (ICPT) on February 25. The company's shares closed last Tuesday at
SmarterAnalyst · 3d ago
The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 1)
Benzinga · 3d ago
eGenesis Announces $125 Million Series C Financing
CAMBRIDGE, Mar 02, 2021 (GLOBE NEWSWIRE via COMTEX) -- CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- eGenesis, a gene-editing and genome-engineering...
GlobeNewswire · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ICPT. Analyze the recent business situations of Intercept through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 24 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ICPT stock price target is 42.87 with a high estimate of 88.00 and a low estimate of 21.00.
EPS
Institutional Holdings
Institutions: 357
Institutional Holdings: 28.24M
% Owned: 85.52%
Shares Outstanding: 33.02M
TypeInstitutionsShares
Increased
57
4.17M
New
68
-2.01M
Decreased
52
3.96M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
Paolo Fundaro
President/Chief Executive Officer/Chief Operating Officer/Director
Jerome Durso
Chief Financial Officer/Treasurer
Sandip Kapadia
Corporate Executive
Lisa Bright
Chief Human Resource Officer
David Ford
Executive Vice President
Christian Weyer
Senior Vice President
Gail Cawkwell
Senior Vice President
Lisa DeFrancesco
Other
Jason Campagna
Other
Linda Richardson
Lead Director/Independent Director
Gino Santini
Independent Director
Srinivas Akkaraju
Independent Director
Luca Benatti
Independent Director
Daniel Bradbury
Independent Director
Keith Gottesdiener
Independent Director
Nancy Miller-Rich
Independent Director
Glenn Sblendorio
Independent Director
Daniel Welch
No Data
  • All
  • Financials
  • Insiders
More
About ICPT
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Webull offers kinds of Intercept Pharmaceuticals Inc stock information, including NASDAQ:ICPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICPT stock methods without spending real money on the virtual paper trading platform.